CSV September 15, 2023 through September 15, 2025 All Errata for USP–NF How to use

×

How to Use

- **Searching:** Type keyword in search field at top of page. Search by all or part of a monograph title. For searches using multiple criteria, you will find items that match each of the specified criteria unless quotation marks are used.
    - For example, a search on Aminosalicylic Acid Tablets will result in anything that contains “Aminosalicyclic” OR “Acid” OR “Tablets”
    - A search for “Aminosalicylic Acid Tablets” will result in anything that specifically contains “Aminosalicylic Acid Tablets”
- **Sorting:** Click on any column header title to sort alphabetically or chronologically in ascending or descending order. Note: the page load column is sorted alphabetically so that a number is ordered by first digit vs. by the actual number; thus, numbers will not always be in order.
    - For example, page 2178 will come before page 74 on a page sort.
- **Downloading:** You can download the Errata table in Comma-separated Value (.csv). The download will include the Errata that you have filtered on.
- **Importing:**You will need to import the file into Excel or Open Office with UTF-8 encoding, as opposed to simply opening it. To import, open Excel or Open Office and select import from the File drop-down. Depending on the version you are using, you should be presented with import formatting options to include UTF-8 as one of the first steps. Importing via UTF-8 should eliminate odd character conversions.

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
LOW-SUBSTIT	*Assay*	*USP35–NF30*	1822	31-Jan-2013	1-Feb-2013	*USP37–NF32*	*Second*	Line 2: Change

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
UTED HYDRO XYPROPYL CELLULOSE							*Supplement to USP36–NF31*	*Hypromellose 2906*, except to substitute *Low-Substituted Hydroxypropyl Cellulose for Hypromellose 2906* throughout. to: *Hypromellose*, except to substitute *Low-Substituted Hydroxypropyl Cellulose for Hypromellose* throughout.
MYRISTYL ALCOHOL	SPECIFIC TESTS/*Fats and Fixed Oils, Hydroxyl Value <401>*	*USP35–NF30*	1873	31-Jan-2013	1-Feb-2013	*USP37–NF32*	*Second Supplement to USP36–NF31*	Line 7 of *Analysis*: Change Result = $[(V_U ? V_B) \times F]/W$ V_U = volume of 1 N sodium hydroxide consumed by the *Sample* (mL) V_B = volume of 1 N sodium

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								hydroxide consumed by the *Blank* (mL) to: Result = [(V_B ? V_U) × F]/W V_B = volume of 1 N sodium hydroxide consumed by the *Blank* (mL) V_U = volume of 1 N sodium hydroxide consumed by the *Sample* (mL)
AMANTADINE HYDROCHLORIDE CAPSULES	PERFORMANCE TESTS/ *Dissolution <711>/Test 2*	*USP35–NF30*	2153	31-Jan-2013	1-Feb-2013	*USP37–NF32*	*Second Supplement to USP36–NF31*	Line 5 of *Chromatographic system*: Change Column: 0.32-mm × 30-cm, 0.25-?m film, phase G1 to: Column: 0.32-mm × 30-m, 0.25-?m film, phase G1
CAPTOPRIL	*Assay*	*USP35–NF30*	2477	31-Jan-2013	1-Feb-2013	*USP37–NF32*	*Second*	Line 1 of *Mobile*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
ORAL SOLUTION							*Supplement to USP36–NF31*	*phase*: Change Prepare a filtered and degassed mixture of methanol and water (11:9) containing 0.5 mL of phosphoric acid. to: Methanol and water (55:45) containing 0.5 mL/L of phosphoric acid. Filter, and degas.
LORATADINE ORALLY-DISINTEGRATING TABLETS	ADDITIONAL REQUIREMENTS/*USP Reference Standards*	*USP35–NF30*	3714	31-Jan-2013	1-Feb-2013	*USP37–NF32*	*Second Supplement to USP36–NF31*	Line 4 of *USP Reference Standards*: Change 8-Chloro-6,11-dihydro-11-(4-piperidylidene)-5*H*-benzo[5,6]cyclohepta[1,2-*b*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								]pyridine. to: 8-Chloro-5,6-dihydro-11-(piperidi
								H -benzo[5,6]cyclohepta[1,2-*b*]pyridine. AND Line 6: Change 310.83 to: 310.82 AND Line 8: Change 8-Chloro-6,11-dihydro -11-(*N* -methyl-4-piperidylidene)-5*H* -benzo[5,6]cyclohepta[1,2-*b*]pyridine. to:

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								8-Chloro-5,6-dihydro-11-(*N*-methylpiperidin-4-ylidene)-11*H*-benzo[5,6]cyclohepta[1,2-*b*]pyridine. AND Line 10: Change 324.88 to: 324.85
NORGESTIMATE	*Limit of residual solvents*	*USP35–NF30*	4083	31-Jan-2013	1-Feb-2013	*USP37–NF32*	*Second Supplement to USP36–NF31*	Line 1 of *Limit of residual solvents*: Change to: *Limit of residual solvents <467>*
ONDANSETRON INJECTION	*USP Reference Standards*	*USP35–NF30*	4120	31-Jan-2013	1-Feb-2013	*USP37–NF32*	*Second Supplement to USP36–NF31*	Line 7: Delete USP Ondansetron Related Compound B RS 6,6´-Methylene

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								bis-[(1,2,3,9-tetrahydro-9-methyl-3-[(2-methyl-1*H*-imidazol-1-yl)-methyl]-4*H*-carbazol-4-one.
OXYBUTYNIN CHLORIDE EXTENDED-RELEASE TABLETS	PERFORMANCE TESTS/ *Dissolution <711>/Test 2*	*USP35–NF30*	4167	31-Jan-2013	1-Feb-2013	*USP37–NF32*	*Second Supplement to USP36–NF31*	Line 3 of *Working standard solution*: Change or transfer 10 mL for Tablets labeled to contain 10 mg, to a 100-mL volumetric flask. to: transfer 10 mL for Tablets labeled to contain 10 mg, or transfer 15 mL for Tablets labeled to

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								contain 15 mg to a 100-mL volumetric flask.
PHENYLALANINE	IMPURITIES	*USP35–NF30*	4296	31-Jan-2013	1-Feb-2013	*USP37–NF32*	*Second Supplement to USP36–NF31*	Line 1 of *Heavy Metals, Method I <231>*: Change *Method I* to: *Method II*
TRIAZOLAM TABLETS	*Assay*	*USP35–NF30*	4936	31-Jan-2013	1-Feb-2013	*USP37–NF32*	*Second Supplement to USP36–NF31*	Line 2: Change *Mobile phase* and *Chromatographic system* —Proceed as directed in the *Assay* under *Triazolam*. to: *Mobile phase*—Prepare a filtered and degassed mixture of acetonitrile, chloroform, butyl alcohol, water, and glacial acetic

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								acid (850:80:50:20:0.5). Make adjustments if necessary (see *System Suitability* under *Chromatography* <621>). AND After the *Assay preparation* subsection: Add a new subsection *Chromatographic system* (see *Chromatography* <621>)—The liquid chromatograph is equipped with a 254-nm detector and a 4.6-mm × 30-cm column that contains packing L3. The flow rate is about 2.0 mL per minute. Chromatograph

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								the *Standard preparation*, and record the peak responses as directed under *Procedure*: the relative retention times are 1 for triazolam and about 1.4 for the internal standard, the resolution, *R*, between the internal standard and triazolam is not less than 2.0, and the relative standard deviation for replicate injections is not more than 2.0%. AND Line 4 of *Procedure*: Change

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								Calculate the quantity, in mg, of $C_{17}H_{12}Cl_2N_4$ in the portion of Triazolam taken by the formula: to: Calculate the quantity, in mg, of $C_{17}H_{12}Cl_2N_4$ in the portion of Tablets taken by the formula: AND Line 9 of *Procedure*: Change R_U and R_S are the ratios of the internal standard peak area to the triazolam peak area obtained from the *Assay preparation* and the *Standard preparation*, respectively. to: *R*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								^{U}and R_S are the ratios of the triazolam peak area to the internal standard peak area obtained from the *Assay preparation* and the *Standard preparation*, respectively.
VINCRISTINE SULFATE	IM PUR ITIES/*Organic Impurities*	*USP35–NF30*	5022	31-Jan-2013	1-Feb-2013	*USP37–NF32*	*Second Supplement to USP36–NF31*	Line 5 of *Analysis*: Change Result = $[r_{UA}/(?r_{UA} + 25r_{UB})] \times 100$ to: Result = $[r_{UA}/(?r_{UA} + 30r_{UB})] \times 100$ AND Change line 12 of *Analysis*: Result = $[?r_{UA}/(?r_{UA} + 25r_{UB})] \times 100$ to: Result = [?*r*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								$^{UA}/(?r_{UA} + 30r_{UB})] \times 100$
ZINC GLUCONATE	IM PURITIES/*Limit of Cadmium*	*USP35–NF30*	5070	31-Jan-2013	1-Feb-2013	*USP37–NF32*	*Second Supplement to USP36–NF31*	Line 22 of *Analysis*: Change *W* = weight of Calcium Gluconate taken to prepare *Sample solution A* (g) to: *W* = weight of Zinc Gluconate taken to prepare *Sample solution A* (g)
ALLANTOIN	IDENTIFICATION	*First Supplement to USP35–NF30*	5429	31-Jan-2013	1-Feb-2013	*USP37–NF32*	*Second Supplement to USP36–NF31*	Line 1 of *B. Thin-Layer Chromatographic Identification Test <201>*: Change The R_F value of the principal spot from *Sample solution A* corresponds to that from *Standard*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								solution A, as described in the test for *Organic Impurities*. to: The R_F value of the principal spot from *Sample solution B* corresponds to that from *Standard solution A*, as described in the test for *Organic Impurities*.
ELEMENTAL IMPURITIES--LIMITS	*Drug Products/Large Volume Parenterals*	*Second Supplement to USP35–NF30*	5633	31-Jan-2013	1-Feb-2013	*USP37–NF32*	*Second Supplement to USP36–NF31*	Row 16 of Column 4 of *Table 1*: Change 70 to: 100 AND Row 16 of Column 5 of *Table 1*: Change 25 to: 10

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
AZITHROMYCIN FOR INJECTION	IM PURITIES/*Limit of Aminoazithromycin, Formamido Analog, Methylformamido Analog, and 3'-De(dimethylamino)-3'-oxoazithromycin (if present)*	*Second Supplement to USP35–NF30*	5910	31-Jan-2013	1-Feb-2013	*USP37–NF32*	*Second Supplement to USP36–NF31*	Line 1 of *Buffer*: Change 3.5 g/mL to: 3.5 g/L
ADAPALENE	IM PUR ITIES/*Residual Solvent: Limit of Triethylamine*	*Revision Bulletin (Official December 01, 2012)*	Online	31-Jan-2013	1-Feb-2013	*USP37–NF32*	*Second Supplement to USP36–NF31*	Line 1 of *Diluent*: Change Dimethyl sulfoxide and 1 N sodium hydroxide solution (4:1) to: Dimethyl sulfoxide AND Line 1 of *Standard solution*: Change 3.2 ?g/mL of USP Triethylamine RS in *Diluent*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								to: 4.0 ?g/mL of USP Triethylamine RS in *Diluent*. Transfer 4.0 mL of this solution to a 20-mL headspace vial, and add 1.0 mL of 1 N NaOH solution. AND Line 1 of *Sample solution*: Change 40 mg/mL of Adapalene in *Diluent* to: 50 mg/mL of Adapalene in *Diluent*. Transfer 4.0 mL of this solution to a 20-mL headspace vial, and add 1.0 mL of 1 N NaOH solution.

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
TACROLIMUS ORAL SUSPENSION	ASSAY/ *Chromatographic system*	*USP36–NF31*	5261	31-Jan-2013	1-Feb-2013	*USP37–NF32*	*Second Supplement to USP36–NF31*	After line 1 of *Column*: Add a new section *Column temperature*: 70°
CAPTOPRIL ORAL SUSPENSION	*Assay*	*USP35–NF30*	2477	31-Jan-2013	1-Feb-2013	*USP37–NF32*	*Second Supplement to USP36–NF31*	Line 1 of *Mobile phase*: Change Prepare a filtered and degassed mixture of methanol and water (11:9) containing 0.5 mL of phosphoric acid. to: Methanol and water (55:45) containing 0.5 mL/L of phosphoric acid. Filter, and degas.
ELEMENTAL IMPURITIES--LIMITS	*Drug Substance and Excipients*	*Second Supplement to USP35–NF30*	5633	31-Jan-2013	1-Feb-2013	*USP37–NF32*	*Second Supplement to USP36–NF31*	Row 16 of Column 4 of *Table 2*: Change 7

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								to: 10
Olanzapine Tablets	ASSAY/ *Procedure*	*Revision Bulletin (Official July 01, 2012)*	Online	30-Nov-2012	1-Dec-2012	*USP37–NF32*	*Second Supplement to USP36–NF31*	Line 10 of *Analysis*: Change C_U = concentration of olanzapine in the *Sample solution* (mg/mL) to: C_U = nominal concentration of olanzapine in the *Sample solution* (mg/mL)
Olanzapine Tablets	IM PUR ITIES/*Organic Impurities*	*Revision Bulletin (Official July 01, 2012)*	Online	30-Nov-2012	1-Dec-2012	*USP37–NF32*	*Second Supplement to USP36–NF31*	Line 11 of *Analysis*: Change C_U = concentration of olanzapine in the *Sample solution* (mg/mL) to: C_U = nominal concentration of olanzapine in

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								the *Sample solution* (mg/mL)
Olanzapine Tablets	ADDITIONAL REQUIREMENTS/*USP Reference Standards <11>*	*Revision Bulletin (Official July 01, 2012)*	Online	30-Nov-2012	1-Dec-2012	*USP37–NF32*	*Second Supplement to USP36–NF31*	Lines 3 and 6: Change USP Olanzapine Related Compound A RS 5-Methyl-2-((2-nitrophenyl)amino)-3-thiophenecarbonitrile. USP Olanzapine Related Compound B RS 2-Methyl-10*H*-thieno-[2,3-*b*][1,5]benzodiazepin-4[5*H*]-one. to: USP Olanzapine Related Compound A

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								RS 5-Methyl-2-((2-nitrophenyl)amino)-3-thiophenecarbonitrile. $C_{12}H_9N_3O_2S$ 259.28 USP Olanzapine Related Compound B RS 2-Methyl-10*H*-thieno-[2,3-*b*][1,5]benzodiazepin-4[5*H*]-one. $C_{12}H_{10}N_2OS$ 230.29
Antibiotics—Microbial Assays	*Turbidimetric Method*	*USP35–NF30*	74	30-Nov-2012	1-Dec-2012	*USP37–NF32*	*Second Supplement to USP36–NF31*	Line 8 of *Analysis*: Change Include in each rack 1–2 control tubes containing 1 mL of the inoculum medium (see *Table 8*) but no

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								antibiotic. to: Include in each rack 1–2 control tubes containing 1 mL of the test diluent (see *Table 7*) but no antibiotic.
Polysorbate 80	SPECIFIC TESTS/*Fats and Fixed Oils, Hydroxyl Value <401>*	*USP35–NF30*	1920	30-Nov-2012	1-Dec-2012	*USP37–NF32*	*Second Supplement to USP36–NF31*	Line 13 of *Analysis*: Change 0.5 N alcoholic potassium hydroxide to: 0.5 N alcoholic potassium hydroxide VS
Polysorbate 80	SPECIFIC TESTS/*Fats and Fixed Oils, Peroxide Value <401>*	*USP35–NF30*	1920	30-Nov-2012	1-Dec-2012	*USP37–NF32*	*Second Supplement to USP36–NF31*	Line 5 of *Analysis*: Change 0.01 M sodium thiosulfate to: 0.01 M sodium thiosulfate VS
Polysorbate 80	SPECIFIC TESTS/*Fats and Fixed Oils,*	*USP35–NF30*	1920	30-Nov-2012	1-Dec-2012	*USP37–NF32*	*Second Supplement to USP36–NF31*	Line 3 of *Analysis*: Change

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
	Saponification Value <401>							0.5 N alcoholic potassium hydroxide to: 0.5 N alcoholic potassium hydroxide VS Line 6 of *Analysis*: Change 0.5 N hydrochloric acid to: 0.5 N hydrochloric acid VS
Aminosalicylate Sodium	*Limit of m-aminophenol*	*USP35–NF30*	2177	30-Nov-2012	1-Dec-2012	*USP37–NF32*	*Second Supplement to USP36–NF31*	Line 1 of *Test preparation*: Change Use the *Assay preparation*, prepared as directed in the *Assay*. to: Transfer about 69 mg of Aminosalicylate Sodium,

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								accurately weighed, to a 100-mL low-actinic volumetric flask, add 50 mL of *Mobile phase*, and swirl to dissolve. Add 10.0 mL of *Internal standard solution*, dilute with *Mobile phase* to volume, and mix.
Aminosalicylate Sodium Tablets	*Limit of m-aminophenol*	*USP35–NF30*	2178	30-Nov-2012	1-Dec-2012	*USP37–NF32*	*Second Supplement to USP36–NF31*	Line 1 of *Test solution*: Change Use the *Assay preparation*, prepared as directed in the *Assay*. to: Weigh and finely powder not fewer than 20 Tablets. Transfer an

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								accurately weighed portion of the powder, equivalent to about 690 mg of aminosalicylate sodium, to a 100-mL low-actinic volumetric flask. Add 50 mL of *Mobile phase*, and shake for about 5 minutes. Dilute with *Mobile phase* to volume, and mix. Filter, and transfer 10.0 mL of the clear filtrate to a low-actinic, 100-mL volumetric flask containing 10.0 mL of *Internal standard solution*, dilute with *Mobile phase* to volume, and

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
Aminosalicylic Acid Tablets	*Limit of m-aminophenol*	*USP35–NF30*	2179	30-Nov-2012	1-Dec-2012	*USP37–NF32*	*Second Supplement to USP36–NF31*	mix. Change the subsection: *Mobile phase* and *Internal standard solution*—Prepare as directed in the *Assay* under *Aminosalicylic Acid*. to: *Mobile phase*—Prepare as directed in the *Assay* under *Aminosalicylic Acid*. *Internal standard solution*—Prepare a solution of sulfanilamide in *Mobile phase* having a concentration of about 5 µg per mL.

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								Line 1 of *Test solution*: Change Use the *Assay preparation*, prepared as directed in the *Assay*. to: Weigh and finely powder not fewer than 20 Tablets. Transfer an accurately weighed portion of the powder, equivalent to about 500 mg of aminosalicylic acid, to a 100-mL low-actinic volumetric flask. Add 50 mL of *Mobile phase*, and shake for about 5 minutes. Dilute with *Mobile phase* to

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								volume, and mix. Filter, and transfer 10.0 mL of the clear filtrate to a 100-mL low-actinic volumetric flask containing 10.0 mL of *Internal standard solution*, dilute with *Mobile phase* to volume, and mix.
Ampicillin Sodium	SPECIFIC TESTS/*pH <791>*	*USP35–NF30*	2213	30-Nov-2012	1-Dec-2012	*USP37–NF32*	*Second Supplement to USP36–NF31*	Line 2: Change text of *Sample solution* from 10.0 mg/mL to: 10.0 mg/mL of ampicillin
Budesonide	ASSAY/ *Procedure*	*USP35–NF30*	2394	30-Nov-2012	1-Dec-2012	*USP37–NF32*	*Second Supplement to USP36–NF31*	Line 2 of *Acceptance criteria*: Change *Epimer A:* 40.0%–51.0% on the dried basis to:

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								Epimer A: 40.0%–51.0%
Dibasic Calcium Phosphate Dihydrate	ASSAY	*USP35–NF30*	2463	30-Nov-2012	1-Dec-2012	*USP37–NF32*	*Second Supplement to USP36–NF31*	Line 14 of *Analysis*: Change *W = Sample weight* (mg) to: *W = Sample weight* (mg) in 20.0 mL of the *Sample solution*
Dibasic Calcium Phosphate Dihydrate	IM PUR ITIES/*Heavy Metals, Method I <231>*	*USP35–NF30*	2463	30-Nov-2012	1-Dec-2012	*USP37–NF32*	*Second Supplement to USP36–NF31*	Line 1 of *Test preparation*: Change Warm 1.3 g with 3 mL of 3 N hydrochloric acid to completely dissolve. to: Warm 1.3 g with 3 mL of 3 N hydrochloric acid until no more dissolves.
Anhydrous Dibasic Calcium Phosphate	ASSAY	*USP35–NF30*	2464	30-Nov-2012	1-Dec-2012	*USP37–NF32*	*Second Supplement to USP36–NF31*	In line 14 of *Analysis*: Change *W = Sample*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								weight (mg) to: *W = Sample* weight (mg) in 20.0 mL of the *Sample solution*
Anhydrous Dibasic Calcium Phosphate	IMPURITIES/*Heavy Metals, Method I <231>*	*USP35–NF30*	2464	30-Nov-2012	1-Dec-2012	*USP37–NF32*	*Second Supplement to USP36–NF31*	Line 1 of *Test preparation*: Change Warm 1.3 g with 3 mL of 3 N hydrochloric acid to completely dissolve. to: Warm 1.3 g with 3 mL of 3 N hydrochloric acid until no more dissolves.
Cod Liver Oil	ASSAY/*Vitamin D*	*USP35–NF30*	2756	30-Nov-2012	1-Dec-2012	*USP37–NF32*	*Second Supplement to USP36–NF31*	Line 1 of *Aqueous potassium hydroxide solution*: Change Dissolve 800 mg of potassium hydroxide in

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								1000 mL of freshly boiled water, mix, and cool. to: Dissolve 800 g of potassium hydroxide in 1000 mL of freshly boiled water, mix, and cool.
Glimepiride Tablets	PERFORMANCE TESTS/ *Dissolution*/*Test 1*	*USP35–NF30*	3335	30-Nov-2012	1-Dec-2012	*USP37–NF32*	*Second Supplement to USP36–NF31*	Line 3 of *Analysis*: Change Result = $(r_U/r_S) \times (C_S/L) \times V \times 100$ to: Result = $(r_U/r_S) \times (C_S/L) \times V \times D \times 100$ AND after Line 8 of *Analysis*: Add *D* = dilution factor of the *Sample solution*
Moxifloxacin Ophthalmic Solution	*Related compounds*/*Test 1*	*USP35–NF30*	3960	30-Nov-2012	1-Dec-2012	*USP37–NF32*	*Second Supplement to USP36–NF31*	Line 4 of *Chromatographic system*:

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
Metronidazole	ASSAY	*USP36–NF31*	4352	30-Nov-2012	1-Dec-2012	*USP37–NF32*	*Second Supplement to USP36–NF31*	Delete The flow rate is about 0.5 mL per minute. Line 8 of *Chromatogaphic system*: Add new subsection after *Injection volume*: *Run time:* Twice the retention time of metronidazole
Tramadol Hydrochloride Tablets	IM PUR ITIES/*Organic Impurities*/*Procedure*	*USP35–NF30*	4905	30-Nov-2012	1-Dec-2012	*USP37–NF32*	*Second Supplement to USP36–NF31*	Line 5 of *Analysis*: Change Result = $(r_U/r_S) \times (C_S/C_U) \times (1/F) \times 0.1$ to: Result = $(r_U/r_S) \times (C_S/C_U) \times (1/F) \times 100$
Triclosan	*Related compounds*	*USP35–NF30*	4939	30-Nov-2012	1-Dec-2012	*USP37–NF32*	*Second Supplement to USP36–NF31*	Line 1 of *Procedure*: Change Inject a volume (about 0.5 µL) to: Inject a volume

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								(about 2.0 µL)
Compound Undecylenic Acid Ointment	*Assay for zinc undecylenate*	*USP35–NF30*	4978	30-Nov-2012	1-Dec-2012	*USP37–NF32*	*Second Supplement to USP36–NF31*	Line 17 of *Procedure*: Change A_U, A_H, and A_L to: A_U, A_{S1}, and A_{S2}
Containers—Glass	SPECIFIC TESTS/ *Hydrolytic Resistance/Method*	*First Supplement to USP35–NF30*	5150	30-Nov-2012	1-Dec-2012	*USP37–NF32*	*Second Supplement to USP36–NF31*	In the Note in line 11 of *Titration*: Change Rinse the grains by swirling with three 15-mL portions of Purified Water, and add the washings to the main solution. to: Rinse the grains by swirling with three 15-mL portions of Carbon Dioxide-Free Water, and add the washings to the main solution.
Esomeprazole Magnesium Del	ASSAY/ *Procedure*	*First Supplement to*	5473	30-Nov-2012	1-Dec-2012	*USP37–NF32*	*Second Supplement to*	Line 1 of *Standard*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
ayed-Release Capsules		*USP35–NF30*					*USP36–NF31*	*solution*: Change Transfer 10 mg of USP Omeprazole RS to a 250-mL volumetric flask, and dissolve in about 10 mL of methanol. to: Transfer 10 mg of USP Omeprazole RS to a 250-mL volumetric flask, and dissolve in about 10 mL of alcohol.
Esomeprazole Magnesium Delayed-Release Capsules	PERFORMANCE TESTS/ *Dissolution <711>*	*First Supplement to USP35–NF30*	5473	30-Nov-2012	1-Dec-2012	*USP37–NF32*	*Second Supplement to USP36–NF31*	Change *Buffer, Diluent, Mobile phase, System suitability, and Chromatographic system*: Proceed as directed in the *Assay*. to: *Buffer, Mobile*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								phase, *System suitability, and Chromatographic system*: Proceed as directed in the *Assay.*
Esterified Estrogens Tablets	ASSAY/ *Procedure*	*First Supplement to USP35–NF30*	5485	30-Nov-2012	1-Dec-2012	*USP37–NF32*	*Second Supplement to USP36–NF31*	Line 3 of *Analysis*: Change Separately calculate the percentage of the labeled amount of sodium estrone sulfate and sodium equilin sulfate in the portion of Conjugated Estrogens taken: to: Separately calculate the percentage of the labeled amount of sodium estrone sulfate and

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								sodium equilin sulfate in the portion of Tablets taken:
Itraconazole	IM PUR ITIES/*Organic Impurities*	*First Supplement to USP35–NF30*	5508	30-Nov-2012	1-Dec-2012	*USP37–NF32*	*Second Supplement to USP36–NF31*	Line 1 of *Standard solution*: Change 1.0 µg/mL of USP Itraconazole RS in *Diluent* to: 10.0 µg/mL of USP Itraconazole RS in *Diluent*
Omega-3-Acid Ethyl Esters Capsules	SPECIFIC TESTS/ *Microbial Enumeration <61>*	*First Supplement to USP35–NF30*	5524	30-Nov-2012	1-Dec-2012	*USP37–NF32*	*First Supplement to USP36–NF31*	Line 2: Change 10^3 to: 10^3 cfu/g AND Line 3: Change 10^2 to: 10^2 cfu/g
Carisoprodol Tablets	ADDITIONAL R EQUIREMENT S/*USP Reference Standards <11>*	*Second Supplement to USP35–NF30*	5921	30-Nov-2012	1-Dec-2012	*USP37–NF32*	*Second Supplement to USP36–NF31*	Line 5: At end of *USP Reference Standards*, add USP

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
Cefepime Hydrochloride	IM PURITIES/*Organic Impurities/Procedure 1: Limit of N-Methylpyrrolidine*	*Second Supplement to USP35–NF30*	5923	30-Nov-2012	1-Dec-2012	*USP37–NF32*	*Second Supplement to USP36–NF31*	Meprobamate RS Line 5 of *Chromatographic system*: Change *Column:* 4.0-mm x 25-cm; 5-µm packing L##[1] to: *Column:* 4.0-mm x 25-cm; 5-µm packing L76 AND Delete corresponding footnote: "Available as Metrosep C4-250."

Pagination

- First page « First
- Previous page ‹ Previous
- …
- Page 32
- Page 33
- Page 34

- Page 35
- Page 36
- Page 37
- Page 38
- Page 39
- Page 40
- Next page Next ›
- Last page Last »